We serve Chemical Name:1-Azatricyclo[3.3.1.1(3,7)]decan-4-one CAS:42949-24-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![1-Azatricyclo[3.3.1.1(3,7)]decan-4-one](https://a.dearchem.com/CAS2/42949-24-6.png)
Chemical Name:1-Azatricyclo[3.3.1.1(3,7)]decan-4-one
CAS.NO:42949-24-6
Synonyms:5-azaadamantan-2-one
Molecular Formula:C9H13NO
Molecular Weight:151.20600
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:265ºC
Density:1.19
Index of Refraction:1.569
PSA:20.31000
Exact Mass:151.10000
LogP:0.46500
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-azaadamantan-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-azaadamantan-2-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-azaadamantan-2-one Use and application,5-azaadamantan-2-one technical grade,usp/ep/jp grade.
Related News: By recapitulating the tumor microenvironment and using a live-cell, function-first approach, Resonant��s platform generates therapeutic candidates that would not be discovered by other methods with unprecedented speed. 1-Azatricyclo[3.3.1.1(3,7)]decan-4-one manufacturer By recapitulating the tumor microenvironment and using a live-cell, function-first approach, Resonant��s platform generates therapeutic candidates that would not be discovered by other methods with unprecedented speed. 1-Azatricyclo[3.3.1.1(3,7)]decan-4-one supplier By recapitulating the tumor microenvironment and using a live-cell, function-first approach, Resonant��s platform generates therapeutic candidates that would not be discovered by other methods with unprecedented speed. 1-Azatricyclo[3.3.1.1(3,7)]decan-4-one vendor The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 1-Azatricyclo[3.3.1.1(3,7)]decan-4-one factory Nearly all patients who got the vaccine developed antibodies designed to head off the spread of abnormal tau while leaving healthy tau proteins intact, Novak said.
